1. Home
  2. ULY vs PPBT Comparison

ULY vs PPBT Comparison

Compare ULY & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urgent.ly Inc.

ULY

Urgent.ly Inc.

HOLD

Current Price

$2.46

Market Cap

5.5M

Sector

N/A

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.66

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULY
PPBT
Founded
2013
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
6.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ULY
PPBT
Price
$2.46
$0.66
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$11.50
N/A
AVG Volume (30 Days)
1.5M
104.4K
Earning Date
03-11-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$127,932,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$0.53
52 Week High
$17.99
$3.86

Technical Indicators

Market Signals
Indicator
ULY
PPBT
Relative Strength Index (RSI) 46.53 46.97
Support Level $2.12 $0.58
Resistance Level $2.75 $0.73
Average True Range (ATR) 0.35 0.04
MACD -0.07 0.00
Stochastic Oscillator 15.13 60.59

Price Performance

Historical Comparison
ULY
PPBT

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: